Bio-Techne and Spear Bio Announce Strategic Partnership to Advance Therapeutic Development with Ultrasensitive Biomarker Detection
Bio-Techne (NASDAQ: TECH) has announced a strategic partnership with Spear Bio to distribute next-generation ultrasensitive immunoassays for neurodegenerative disease research. The partnership follows Bio-Techne's participation in Spear Bio's $45 million Series A funding in 2024.
The collaboration will focus on distributing Spear Bio's SPEAR platform technology, which offers 2-3 orders of magnitude higher sensitivity than current immunoassay platforms. The initial offering targets key Alzheimer's disease biomarkers including pTau 217, GFAP, Nf-L, and pTau 231.
This partnership leverages Bio-Techne's global distribution network and immunoassay expertise with Spear Bio's ultrasensitive technology to advance early disease detection and therapeutic development.
Bio-Techne (NASDAQ: TECH) ha annunciato una partnership strategica con Spear Bio per la distribuzione di immunoassay ultrasensibili di nuova generazione dedicati alla ricerca sulle malattie neurodegenerative. Questa collaborazione segue la partecipazione di Bio-Techne al finanziamento Series A da 45 milioni di dollari di Spear Bio nel 2024.
La collaborazione si concentrer脿 sulla distribuzione della tecnologia piattaforma SPEAR di Spear Bio, che garantisce una sensibilit脿 superiore di 2-3 ordini di grandezza rispetto alle piattaforme immunoassay attuali. L'offerta iniziale 猫 focalizzata sui principali biomarcatori dell'Alzheimer, tra cui pTau 217, GFAP, Nf-L e pTau 231.
Questa partnership sfrutta la rete di distribuzione globale e l'expertise in immunoassay di Bio-Techne insieme alla tecnologia ultrasensibile di Spear Bio per promuovere la diagnosi precoce delle malattie e lo sviluppo di terapie.
Bio-Techne (NASDAQ: TECH) ha anunciado una asociaci贸n estrat茅gica con Spear Bio para distribuir inmunoensayos ultrasensibles de pr贸xima generaci贸n para la investigaci贸n de enfermedades neurodegenerativas. La asociaci贸n se produce tras la participaci贸n de Bio-Techne en la ronda de financiaci贸n Serie A de 45 millones de d贸lares de Spear Bio en 2024.
La colaboraci贸n se centrar谩 en distribuir la tecnolog铆a de plataforma SPEAR de Spear Bio, que ofrece una sensibilidad 2-3 贸rdenes de magnitud superior a las plataformas de inmunoensayo actuales. La oferta inicial se dirige a biomarcadores clave de la enfermedad de Alzheimer, incluyendo pTau 217, GFAP, Nf-L y pTau 231.
Esta asociaci贸n aprovecha la red global de distribuci贸n y la experiencia en inmunoensayos de Bio-Techne junto con la tecnolog铆a ultrasensible de Spear Bio para avanzar en la detecci贸n temprana de enfermedades y el desarrollo terap茅utico.
Bio-Techne (NASDAQ: TECH)电� Spear Bio鞕� 鞝勲灥鞝� 韺岉姼雱堨嫮鞚� 觳搓舶頃橃棳 鞁犼步韲错枆靹� 歆堩櫂 鞐瓣惮毳� 鞙勴暅 彀劯雽� 齑堦皭霃� 氅挫棴旄§爼氩曥潉 氚绊彫頃滊嫟瓿� 氚滍憸頄堨姷雼堧嫟. 鞚措矆 韺岉姼雱堨嫮鞚� 2024雲� Spear Bio鞚� 4,500毵� 雼煬 攴滊 鞁滊Μ歃� A 韴瀽鞐� Bio-Techne臧� 彀胳棳頃� 雿� 霐半ジ 瓴冹瀰雼堧嫟.
鞚措矆 順戨牓鞚� Spear Bio鞚� SPEAR 頂岆灚韽� 旮办垹 氚绊彫鞐� 欷戩爯鞚� 霊愲┌, 鞚吹鐢 旮办〈 氅挫棴旄§爼 頂岆灚韽茧炒雼� 2~3雼硠 雴掛潃 臧愲弰毳� 鞝滉车頃╇媹雼�. 齑堦赴 鞝滍拡鞚� pTau 217, GFAP, Nf-L, pTau 231 霌� 鞎岇笭頃橃澊毹鸽硲 欤检殧 氚旍澊鞓る旎るゼ 雽�靸侅溂搿� 頃╇媹雼�.
鞚措矆 韺岉姼雱堨嫮鞚� Bio-Techne鞚� 旮�搿滊矊 鞙犿喌毵濌臣 氅挫棴旄§爼 鞝勲靹膘棎 Spear Bio鞚� 齑堦皭霃� 旮办垹鞚� 瓴绊暕頃橃棳 臁瓣赴 歆堧硲 歆勲嫧瓿� 旃橂 臧滊皽鞚� 齑夓頃╇媹雼�.
Bio-Techne (NASDAQ : TECH) a annonc茅 un partenariat strat茅gique avec Spear Bio pour distribuer des immunoessais ultrasensibles de nouvelle g茅n茅ration d茅di茅s 脿 la recherche sur les maladies neurod茅g茅n茅ratives. Ce partenariat fait suite 脿 la participation de Bio-Techne au financement de s茅rie A de 45 millions de dollars de Spear Bio en 2024.
La collaboration portera sur la distribution de la technologie de plateforme SPEAR de Spear Bio, offrant une sensibilit茅 2 脿 3 ordres de grandeur sup茅rieure aux plateformes d'immunoessais actuelles. L'offre initiale cible les principaux biomarqueurs de la maladie d'Alzheimer, notamment pTau 217, GFAP, Nf-L et pTau 231.
Ce partenariat combine le r茅seau mondial de distribution et l'expertise en immunoessais de Bio-Techne avec la technologie ultrasensible de Spear Bio afin de faire progresser la d茅tection pr茅coce des maladies et le d茅veloppement th茅rapeutique.
Bio-Techne (NASDAQ: TECH) hat eine strategische Partnerschaft mit Spear Bio angek眉ndigt, um ultrasensitive Immunoassays der n盲chsten Generation f眉r die Forschung an neurodegenerativen Erkrankungen zu vertreiben. Die Partnerschaft folgt auf die Beteiligung von Bio-Techne an der 45 Millionen US-Dollar Series A Finanzierung von Spear Bio im Jahr 2024.
Der Fokus der Zusammenarbeit liegt auf dem Vertrieb der SPEAR Plattformtechnologie von Spear Bio, die eine 2-3 Gr枚脽enordnungen h枚here Sensitivit盲t als aktuelle Immunoassay-Plattformen bietet. Das erste Angebot richtet sich auf wichtige Alzheimer-Biomarker wie pTau 217, GFAP, Nf-L und pTau 231.
Diese Partnerschaft nutzt das globale Vertriebsnetz und die Immunoassay-Expertise von Bio-Techne zusammen mit der ultrasensitiven Technologie von Spear Bio, um die Fr眉herkennung von Krankheiten und die Entwicklung von Therapien voranzutreiben.
- Partnership enables detection of biomarkers with 100-1000x higher sensitivity than current platforms
- Expands Bio-Techne's presence in high-growth neurodegenerative disease markets
- Strategic investment through participation in Spear Bio's $45M Series A funding
- Leverages Bio-Techne's global distribution network for market expansion
- None.
Insights
Bio-Techne's partnership with Spear Bio strengthens its position in the high-growth neurodegenerative biomarker market with superior detection technology.
This strategic partnership between Bio-Techne and Spear Bio represents a significant technological advancement in the biomarker detection landscape. Spear Bio's SPEAR platform delivers 2-3 orders of magnitude higher sensitivity than current immunoassay platforms 鈥� a dramatic improvement that could fundamentally change how neurodegenerative diseases are researched and eventually diagnosed.
The initial focus on Alzheimer's biomarkers is strategically sound. The ability to detect key markers like pTau 217, GFAP, Nf-L, and pTau 231 with unprecedented sensitivity addresses a critical unmet need in neurodegenerative research. This positions Bio-Techne to capture value in the growing market for precision neurology tools.
Bio-Techne's previous participation in Spear Bio's
The technology's relevance beyond neurology to inflammation and oncology suggests substantial market expansion potential. For Bio-Techne investors, this partnership represents both immediate revenue opportunities through distribution and longer-term strategic value as biomarker-driven approaches gain further traction in therapeutic development and clinical practice.
Early detection of protein biomarkers is essential for understanding historically challenging disease mechanisms, developing early interventions, and advancing clinical trials. Spear Bio's Successive Proximity Extension Amplification Reaction (SPEAR) platform, based on breakthrough technology licensed from Harvard University, and amplified using conventional qPCR instrumentation, offers sensitivity two to three orders of magnitude higher than current immunoassay platforms.
"Partnering with Spear Bio marks an exciting step in our mission to advance biomarker detection in neurodegenerative disease research" said Will Geist, President of Bio-Techne's Protein Sciences Segment. "By leveraging Bio-Techne's global reach and immunoassay expertise with Spear Bio's ultrasensitive technology, we are equipping researchers with innovative tools to detect and study critical biomarkers with unmatched precision and sensitivity."
With Bio-Techne's global reach, Spear Bio is well-positioned to accelerate the deployment of its next-generation assay technology, enabling researchers to detect biomarkers in historically challenging conditions. Spear Bio's initial focus is neurodegenerative diseases, with the technology relevant for inflammation, oncology and additional fields. In addition, Spear Bio's advanced detection technology expands applications in high-growth markets, including early neurodegenerative disease diagnosis, enhancing patient access to critical interventions.
"Our strategic partnership with Bio-Techne represents a transformative opportunity for neurodegenerative disease research," said Feng Xuan, PhD, Founder and CEO of Spear Bio. "By combining Bio-Techne's global distribution network and market leadership with Spear Bio's next-generation immunoassay technology, we are empowering researchers worldwide to investigate earlier disease mechanisms, improve patient stratification in clinical trials, and accelerate the development of new treatments for neurological disorders."
This partnership underscores the promise of Spear Bio's SPEAR technology and reinforces Bio-Techne's commitment to advancing biomarker detection.
About Bio-Techne
Bio-Techne Corporation (NASDAQ: TECH) is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities. Bio-Techne products assist scientific investigations into biological processes and the nature and progress of specific diseases. They aid in drug discovery efforts and provide the means for accurate clinical tests and diagnoses. With hundreds of thousands of products in its portfolio, Bio-Techne generated approximately
About Spear Bio
Founded in 2021 and headquartered in
To learn more about the company, please visit .
Bio-Techne听Contact:
David Clair, Vice President, Investor Relations & Corporate Development
[email protected]
612-656-4416听
Spear Bio Media Contact:
View original content to download multimedia:
SOURCE Bio-Techne Corporation
FAQ
What is the partnership between Bio-Techne (NASDAQ: TECH) and Spear Bio?
How much more sensitive is Spear Bio's SPEAR platform compared to current technologies?
What was Bio-Techne's investment in Spear Bio?
Which disease areas will the Bio-Techne and Spear Bio partnership initially focus on?
How will the Bio-Techne partnership help Spear Bio's market reach?
